Publications by authors named "Yaming Su"

Claim this Profile
T
Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma.
Yue Guo, Jin Niu, Natalia A Quijano Cardé, Liviawati Wu, Xin Miao, Yaming Su

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Nahor Haddish-Berhane, Yaming Su, Alberto Russu, Meena Thayu, Roland E Knoblauch, Yu-Nien Sun

Clin Pharmacol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yaming Su, Suzette Girgis

Target Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease.
Jie Zhou, Yan Xu, Yang Chen, Jie Shao, Yaming Su

J Clin Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Liviawati S Wu, Yaming Su, Claire Li, Wangda Zhou, Carolyn C Jackson, Yu-Nien Sun

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis.
Christine Xu, Yaming Su, Anne Paccaly, Vanaja Kanamaluru

Clin Pharmacokinet· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
John Kuruvilla, Cheng-Hwai Tzeng, Seok-Goo Cho, Seok Jin Kim, Jih-Luh Tang, Yaming Su

Bone Marrow Transplant· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, Valeriu Damian-Iordache, Christopher Gibson, Cheng-Pang Hsu, Satyendra Suryawanshi, Yaming Su

AAPS J· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The A to G polymorphism at -1082 of the interleukin-10 gene is rare in the Han Chinese population.
Jing Guo, Yong-Hui He, Feng Chen, Min-Hui Jiang, Shu-Ping Gao, Ya-Ming Su

Mol Med Rep· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Yaming Su, Peidi Hu, Sung-Hack Lee, Patrick J Sinko

J Pharm Pharm Sci· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: a promising new approach to the treatment of multidrug resistant cancer.
Yaming Su, Xiaoping Zhang, Patrick J Sinko

Cancer Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Yaming Su, Sung-Hack Lee, Patrick J Sinko

Eur J Pharm Sci· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it?
Yaming Su, Patrick J Sinko

Expert Opin Drug Deliv· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative assessment of the cell penetrating properties of RI-Tat-9: evidence for a cell type-specific barrier at the plasma membrane of epithelial cells.
Xiaoping Zhang, Li Wan, Shahriar Pooyan, Yaming Su, Carol R Gardner

Mol Pharm· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical aspects of transporter model systems: a case study involving SQV.
Yaming Su, Sung-Hack Lee, Patrick J Sinko

Drug Metab Rev· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
Yaming Su, Xiaoping Zhang, Patrick J Sinko

Mol Pharm· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galanin down-regulates microglial tumor necrosis factor-alpha production by a post-transcriptional mechanism.
Yaming Su, Doina Ganea, Xiaorong Peng, G Miller Jonakait

J Neuroimmunol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis